The EMJ Podcast | Episode 244
In this episode, Jonathan Sackier welcomes Andrew Blauvelt, a distinguished dermatologist and leading expert in immunodermatology. They discuss groundbreaking advancements in psoriasis treatment, including the role of high-dose biologics in achieving deep remission and how IL-23 inhibition is transforming long-term disease management.
Spotify | Apple | Amazon Music | Download MP3 (44 mins)
Andrew Blauvelt is a consultant at Blauvelt Consulting and a distinguished leader in dermatology, with a career spanning research, clinical practice, and industry collaborations. Renowned for his pioneering work in immunodermatology, he has played a pivotal role in advancing the understanding of IL-23 and Th17 pathways in psoriasis. A respected researcher and thought leader, has led numerous high-impact clinical trials, including the groundbreaking KNOCKOUT study, which investigated the effects of high-dose risankizumab on disease recurrence. His expertise bridges the gap between academia and industry, driving innovation in inflammatory disease management.
